Abbokinase Open-Cath Disease Interactions
There are 2 disease interactions with Abbokinase Open-Cath (urokinase).
Thrombolytic agents (applies to Abbokinase Open-Cath) bleeding risks
Major Potential Hazard, High plausibility. Applicable conditions: Gastrointestinal Hemorrhage, Cerebral Vascular Disorder, Retinal Hemorrhage, Hypertension, Infectious Endocarditis
The use of thrombolytics is contraindicated in patients with an active bleed (internal), trauma/surgery (recent CPR/intracranial/intraspinal surgery within 2 months), bleeding diathesis, history of cerebrovascular (CV) accident, intracranial defect (aneurysm, arteriovenous malformation, neoplasm), or severe uncontrolled arterial hypertension (SBP>180/DBP>110). Risk versus benefit should be carefully considered in the following conditions and thrombolytic therapy administered with caution in patients with recent (10 days) serious GI bleed or recent (10 days) surgical procedure (coronary bypass graft, obstetrical delivery, organ biopsy, puncture of noncompressible vessel), left heart thrombus, subacute bacterial endocarditis, hemostatic defect, CV disease, diabetic hemorrhagic retinopathy, or pregnancy. Clinical monitoring of hematopoietic, bleeding and coagulation functions is recommended prior to initiation of thrombolytic therapy. Measures of fibrinolytic activity and/or coagulation functions during infusion do not correlate with efficacy or risk of bleeding.
Urokinase (applies to Abbokinase Open-Cath) liver disease
Moderate Potential Hazard, Moderate plausibility.
Urokinase undergoes extensive clearance and degradation by the liver. The pharmacokinetic disposition of urokinase has not been fully determined, however it is expected that the half-life of urokinase would be prolonged in patients with hepatic impairment. Therapy with urokinase should be administered cautiously in patients with compromised hepatic function. Clinical monitoring of bleeding functions should be determined prior to initiation of therapy. Measures of fibrinolytic activity and/or coagulation functions during infusion do not correlate with efficacy or risk of bleeding.
Switch to professional interaction data
Abbokinase Open-Cath drug interactions
There are 154 drug interactions with Abbokinase Open-Cath (urokinase).
Abbokinase Open-Cath alcohol/food interactions
There is 1 alcohol/food interaction with Abbokinase Open-Cath (urokinase).
More about Abbokinase Open-Cath (urokinase)
- Check interactions
- Compare alternatives
- Side effects
- Dosage information
- During pregnancy
- Drug class: thrombolytics
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.